title: Cost Effectiveness Analysis of Everolimus + Exemestane for Patients with Advanced Breast Cancer with Positive Estrogen Receptor (ER +), HER2-, Refractory to Non-Steroidal Aromatase Inhibitors (NSAIS) in Chile.
authors.affiliation: Novartis Pharmaceuticals, Buenos Aires, Argentina.
authors.forename: B
authors.initials: B
authors.lastname: Ratto
authors.affiliation: INSTITUTO NACIONAL DEL CÁNCER, Santiago, Chile.
authors.forename: Ulloa R
authors.initials: UR
authors.lastname: Torres
authors.affiliation: INSTITUTO NACIONAL DEL CÁNCER, Santiago, Chile.
authors.forename: Veneros H
authors.initials: VH
authors.lastname: Cerda
authors.affiliation: Novartis Pharmaceuticals, Mexico City, Mexico.
authors.forename: P
authors.initials: P
authors.lastname: Anaya